HUANG et al. V. PRASIT et al. - Page 32




                    k.  Reliance on scientific tests and data                         
                    Parties often rely on scientific tests and data,                  
               both in the preliminary motion phase and during the                    
               priority testimony phase.  Examples include IR                         
               (infra-red spectroscopy) and graphs generated                          
               therefrom, HPLC (high performance liquid                               
               chromatography) and data generated therefrom, etc.                     
               In the event a party relies on a scientific test or                    
               data generated from a scientific test, the party                       
               relying on the test or data shall explain:                             
                         1.   the reason why the test is being used                   
                              and why the data is being relied upon;                  
                         2. how the test is performed;                                
                         3.   how the data is generated using the                     
                              test;                                                   
                         4.   how the data is used to determine a                     
                              value;                                                  
                         5.   the acknowledged accuracy of the test;                  
                              and                                                     
                         6.   any other information which would aid                   
                              the board in understanding the                          
                              significance of the test or data.                       
          See also 37 CFR § 1.671(f) and Notice of Final Rule, Patent                 
          Interferences Proceedings, 49 Fed. Reg. 48416, 48427-28, 48447              
          (col. 3) (Dec. 12, 1984).                                                   
               In her testimony, Koboldt stated an opinion, i.e., that                
          she expected SC-58394 to have good COX-2 inhibitory                         
          selectivity, without explaining or interpreting the data upon               
          which the opinion is based.  While Koboldt testified that she               
                                         32                                           





Page:  Previous  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  Next 

Last modified: November 3, 2007